Selection of our recently published works

  • Vyoral D, Petrak J. Therapeutic potential of hepcidin - the master
    regulator of iron metabolism. Pharmacol Res. 2017 Jan; 115:242-254.

  • Melenovsky V, Petrak J, Mracek T, Benes J, Borlaug BA, Nuskova H, Pluhacek T,
    Spatenka J, Kovalcikova J, Drahota Z, Kautzner J, Pirk J, Houstek J. Myocardial
    iron content and mitochondrial function in human heart failure: a direct tissue
    analysis. Eur J Heart Fail. 2017 Apr;19(4):522-530

  • Vit O, Petrak J. Integral membrane proteins in proteomics. How to break open the black box? J Proteomics. 2017 Feb 5;153:8-20 Review. (here)

  • Sedmera D, Neckar J, Benes J Jr, Pospisilova J, Petrak J, Sedlacek K,
    Melenovsky V. Changes in Myocardial Composition and Conduction Properties in Rat
    Heart Failure Model Induced by Chronic Volume Overload. Front Physiol. 2016 Aug 25;7:367.

  • Toman O, Kabickova T, Vit O, Fiser R, Polakova KM, Zach J, Linhartova J,Vyoral D, Petrak J. Proteomic analysis of imatinib-resistant CML-T1 cells reveals calcium homeostasis as a potential therapeutic target. Oncol Rep. 2016 Sep;36(3):1258-68. (here)

  • Vit O, Man P, Kadek A, Hausner J, Sklenar J, Harant K, Novak P, Scigelova M,Woffendin G, Petrak J. Large-scale identification of membrane proteins based onanalysis of trypsin-protected transmembrane segments. J Proteomics. 2016 Oct 21;149:15-22 (here)

  • Lorkova L, Scigelova M, Arrey TN, Vit O, Pospisilova J, Doktorova E, Klanova M, Alam M, Vockova P, Maswabi B, Klener P Jr, Petrak J. Detailed Functional and Proteomic Characterization of Fludarabine Resistance in Mantle Cell Lymphoma Cells. PLoS One. 2015 Aug 18;10(8):e0135314.  (here)

  • Klanova M, Lorkova L, Vit O, Maswabi B, Molinsky J, Pospisilova J, Vockova P, Mavis C, Lateckova L, Kulvait V, Vejmelkova D, Jaksa R, Hernandez F, Trneny M, Vokurka M, Petrak J, Klener P Jr. Downregulation of deoxycytidine kinase in cytarabine-resistant mantle cell lymphoma cells confers cross-resistance to nucleoside analogs gemcitabine, fludarabine and cladribine, but not to other classes of anti-lymphoma agents. Mol Cancer. 2014 Jun 27;13(1):159. (here)

  • Pospisilova J, Vit O, Lorkova L, Klanova M, Zivny J, Klener P, Petrak J Resistance to TRAIL in mantle cell lymphoma cells is associated with decreased expression of purine metabolism enzymes. Int J Mol Med. May;31(5):1273-9. 2013.  (here)

  • Sillerova T, Zivny J, Vyoral D, Petrak J. Nutritional hepatic iron overload is not prevented by parenteral hepcidin substitution therapy in mice. Br J Nutr. 2012 Nov;108(10):1723-5.  (here) 

  • Lorkova L, Pospisilova J, Lacheta J, Leahomschi S, Zivny J, Cibula D, Zivny J, Petrak J. Decreased concentrations of retinol-binding protein 4 in sera of epithelial ovarian cancer patients: a potential biomarker identified by proteomics. Oncol Rep. 2012 Feb;27(2):318-24. (here)  

  • Petrak J, Pospisilova J, Sedinova M, Jedelsky P, Lorkova L, Vit O, Kolar M, Strnad H, Benes J, Sedmera D, Cervenka L, Melenovsky V. Proteomic and transcriptomic analysis of heart failure due to volume overload in a rat aorto-caval fistula model provides support for new potential therapeutic targets - monoamine oxidase A and transglutaminase 2. Proteome Sci. 2011 Nov 11;9(1):69. (here)